Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Metastatic RCC Eligible for Cytoreductive Nephrectomy
NCT00715442Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2008
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2008; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00715442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715442.